AXL and metabolic dysfunction-associated steatohepatitis: A consistent reduction in collagen content, visualized in Sirius Red slides in bemcentinib doses from 100 to 3 mg/kg (Figure 6A), was accompanied by a significant transcriptional decrease in profibrotic (Figure 6B) and inflammation-related genes (Figure 6C), consistent with the beneficial effect of AXL inhibition during the development of experimental MASH (4).